Clinical Trial ProgressSernova's Phase 1/2 study results are indicative of the trial being on track to succeed and help de-risk any upcoming data readouts and subsequent studies.

Product InnovationThe addition of tegoprubart to Sernova’s Cell Pouch platform is expected to enable patients to achieve insulin independence with significantly less toxicity.

Research CollaborationA new research agreement with Eledon Pharmaceuticals aims to enhance cell pouch safety in Sernova's clinical development, potentially improving the therapy for patients with type 1 diabetes.

Bears Say

Sernova News

Sernova Biotherapeutics Advances Diabetes Treatment with New Funding

Sernova ( ($TSE:SVA) ) has shared an announcement. Sernova Biotherapeutics has successfully closed the first tranche of a...

3M ago

Sernova Biotherapeutics Strengthens Financial Position with Debt-to-Equity Conversion

Sernova ( ($TSE:SVA) ) has provided an announcement. Sernova Biotherapeutics announced a significant financial restructuring by converting approximately...

4M ago

Sernova Biotherapeutics Appoints John L. Brooks III as Board Chair to Advance Diabetes Cure

The latest announcement is out from Sernova ( ($TSE:SVA) ). Sernova Biotherapeutics has appointed John L. Brooks III...

4M ago

Sernova Biotherapeutics to Present at Global Investment Conference

Sernova ( ($TSE:SVA) ) has issued an update. Sernova Biotherapeutics announced its participation in the H.C. Wainwright 27th...

5M ago

Sernova and Eledon Collaborate on Potential Type 1 Diabetes Cure

The latest update is out from Sernova ( ($TSE:SVA) ). Sernova Biotherapeutics has announced a collaboration with Eledon...

7M ago

Promising Advancements and Strategic Partnerships Bolster Sernova’s Buy Rating for T1D Treatment

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Sernova today and set a price target of...

7M ago

Sernova’s Promising T1D Treatment Strategy Gains Confidence with External Validation and Unique Cell Pouch System

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Sernova (SVA – Research Report) today and set...

8M ago

Sernova Biotherapeutics Appoints Interim Chair Amid Strategic Advancements

Sernova ( ($TSE:SVA) ) has shared an announcement. Sernova Biotherapeutics has appointed its CEO, Jonathan Rigby, as the...

8M ago

Sernova Biotherapeutics Forms Clinical Advisory Board to Advance Diabetes Treatment

Sernova ( ($TSE:SVA) ) just unveiled an announcement. Sernova Biotherapeutics has announced the formation of a Clinical Advisory...

9M ago

Sernova’s Cell Pouch Shows Promising Results in Diabetes Trial

Sernova ( ($TSE:SVA) ) has provided an update. Sernova Biotherapeutics announced positive interim data from its ongoing Phase...

9M ago

SVA FAQ

What was Sernova’s price range in the past 12 months?

Sernova lowest stock price was C$0.12 and its highest was C$0.23 in the past 12 months.

What is Sernova’s market cap?

Sernova’s market cap is C$53.87M.

When is Sernova’s upcoming earnings report date?

Sernova’s upcoming earnings report date is Mar 19, 2026 which is in 44 days.

How were Sernova’s earnings last quarter?

Sernova released its earnings results on Dec 19, 2025. The company reported -C$0.005 earnings per share for the quarter, beating the consensus estimate of -C$0.01 by C$0.005.

Is Sernova overvalued?

According to Wall Street analysts Sernova’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sernova pay dividends?

Sernova does not currently pay dividends.

What is Sernova’s EPS estimate?

Sernova’s EPS estimate is >-0.01.

How many shares outstanding does Sernova have?

Sernova has 336,698,550 shares outstanding.

What happened to Sernova’s price movement after its last earnings report?

Sernova reported an EPS of -C$0.005 in its last earnings report, beating expectations of -C$0.01. Following the earnings report the stock price went up 3.846%.

Which hedge fund is a major shareholder of Sernova?

Currently, no hedge funds are holding shares in TSE:SVA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sernova

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.